title: Klebsiella pneumoniae meningitis: analysis on clinical features of thirty-two adult patients.
abstract: BACKGROUND
  To assess the clinical features and therapeutic outcomes of adult Klebsiella pneumoniae (KP) meningitis.
  
  
  METHODS
  Thirty-two adult patients with KP meningitis were included in this study. Their clinical features, the outcomes with the third generation cephalosporin (moxalactam, cefotaxime, ceftazidime) treatment and prognostic factors were analyzed.
  
  
  RESULTS
  These patients' diseases were predominantly community-acquired. Males outnumbered females (3:1). Diabetes mellitus (DM) was the most common underlying disease, followed by other debilitating diseases such as liver cirrhosis, neoplasm and end-stage renal disease (ESRD). Patients with spontaneous meningitis had a more fulminant course with a higher prevalence of bacteremia, shock and death (66%). Metastatic septic abscess was frequent (19%). Among the 21 patients who received initial appropriate antimicrobial therapy (IAAT), 2 took cefotaxime and 1 died; 13 took moxalactam of whom 5 died; and 6 took ceftazidime of whom 3 died. All of the other 11 patients who did not receive IAAT died.
  
  
  CONCLUSIONS
  The clinical features of KP meningitis are various and indistinguishable from other form of bacteria meningitis. Most of the patients with KP meningitis are associated with underlying medical problems, such as diabetes mellitus and liver cirrhosis. Many factors, including septic shock, bacteremia, high cerebrospinal fluid lactate concentration, and IAAT, might influence the prognosis. In spite of a high mortality rate, however, IAAT is mandatory to improve the overall survival rate.
authors.affiliation: Department of Neurology, Chang Gung Memorial Hospital, Kaohsiung, Taiwan.
authors.forename: C H
authors.initials: CH
authors.lastname: Lu
authors.forename: W N
authors.initials: WN
authors.lastname: Chang
authors.forename: H S
authors.initials: HS
authors.lastname: Wu
mesh_terms: D000328:Adult; D000368:Aged; D002511:Cephalosporins / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007710:Klebsiella Infections / Q000188:drug therapy*; D007711:Klebsiella pneumoniae; D008297:Male; D016920:Meningitis, Bacterial / Q000188:drug therapy*; D008875:Middle Aged; D011379:Prognosis
chemical_list: D002511:Cephalosporins